GeoVax Labs (GOVX) Operating Income (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Operating Income of -$4.4 million for Q2 2026, up 18.03% year-over-year from -$3.8 million in Q2 2025, and little changed quarter-over-quarter from -$4.4 million in Q4 2025.
GeoVax Labs (GOVX) Operating Income (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Operating Income for 17 consecutive years, with -$4.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income rose 18.03% year-over-year to -$4.4 million; the TTM figure through Jun 2026 stood at -$20.7 million (up 17.37% YoY), while the FY2025 annual figure was -$21.6 million, up 13.94% from the prior year.
- Operating Income was little changed at -$4.4 million in Q2 2026 per GOVX's latest filing, from -$4.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.2 million in Q2 2022 and bottomed at -$8.6 million in Q3 2023.
- Historically, Operating Income has averaged -$5.4 million across 5 years, with a median of -$5.4 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Income surged 60.8% — and 2023, when it slumped 175.53%.
- GeoVax Labs' Operating Income stood at -$5.4 million in 2022, then tumbled by 42.81% to -$7.7 million in 2023, then dropped by 8.46% to -$8.3 million in 2024, then surged by 46.77% to -$4.4 million in 2025, then dropped by 0.01% to -$4.4 million in 2026.
- Business Quant data shows GOVX's Operating Income at -$4.4 million in Q2 2026, -$4.4 million in Q4 2025, and -$6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | -4.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.44 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | -5.42 Mn |
| Mar 31, 2025 | -5.41 Mn |
| Dec 31, 2024 | -8.34 Mn |
| Sep 30, 2024 | -5.85 Mn |
| Jun 30, 2024 | -5.06 Mn |
| Mar 31, 2024 | -5.88 Mn |
| Dec 31, 2023 | -7.69 Mn |
| Sep 30, 2023 | -8.60 Mn |
| Jun 30, 2023 | -6.18 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -5.39 Mn |
| Sep 30, 2022 | -3.97 Mn |
| Jun 30, 2022 | -2.24 Mn |
| Mar 31, 2022 | -2.43 Mn |
| Dec 31, 2021 | -13.74 Mn |
| Sep 30, 2021 | -1.95 Mn |
| Jun 30, 2021 | -1.49 Mn |